Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Bone-Targeting Microspheres Enable Sustained Release of CD301b<sup>+</sup> Macrophage-Derived Small Extracellular Vesicles to Promote Bone Repair

Gao X., Ma S., Dong Y., Yang F., Huang R., Zheng X.

Animal Study on Immune Modulation, published in Theranostics (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Theranostics (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42370173
PMCID
PMC13295118
DOI
10.7150/thno.132666

Abstract (original English)

Rationale Large bone defects often exceed the body's intrinsic capacity for self-repair. Successful bone healing depends on a coordinated immune transition alongside tightly coupled angiogenesis and osteogenesis, in which macrophages play a key regulatory role. Therefore, ideal bone-regenerative materials should integrate immunomodulatory, pro-angiogenic, and osteogenic functions. Methods and results Small extracellular vesicles (sEVs) from CD301b + macrophages (CD301b⁺-sEVs) are isolated by ultracentrifugation for inclusion in a bone-targeting microsphere system fabricated by microfluidic technology through dynamic Schiff-base cross-linking of alendronate-functionalized succinylated chitosan with oxidized sodium alginate allowing pH-responsive release of CD301b⁺-sEVs. Transcriptome sequencing and comprehensive in vitro studies reveal that CD301b⁺-sEVs possess the ability to modulate immune homeostasis by promoting macrophage polarization toward the pro-repair M2 phenotype, upregulate angiogenic factors that can enhance vascularization as seen by HUVEC sprouting assay, and contain RNA that stimulate osteogenic differentiation of BMSCs through activation of the Akt/GSK-3β/β-catenin signaling pathway. Preclinical studies with a rat calvaria model show that microspheres loaded with CD301b + -sEVs significantly promote bone regeneration in comparison to microsphere controls. Conclu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MacrophagesAnimalsHumansRatsDelayed-Action PreparationsMicrospheresExtracellular VesiclesBone RegenerationOsteogenesis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research